Dr. Whitman on the Role of Pembrolizumab in Melanoma

Video

Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.

Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.

Being treated with pembrolizumab has provided a longer life for patients with melanoma, says Whitman. Previously, patients with metastatic melanoma would be put on clinical trials, but the outcomes were not successful. However, now with the addition of pembrolizumab, patients seem to be doing quite well, Whitman adds.

There are many toxicities that are intrinsic to treatment with pembrolizumab. Physicians are often used to chemotherapy-related toxicities, such as hair loss or tongue swelling, but toxicities associated with immunotherapy are different, explains Whitman. Since these drugs affect the immune system, the side effects are mostly autoimmune-related.

In the phase III EORTC1325/KEYNOTE-054 trial, adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma. The hazard ratio for recurrence-free survival was 0.57 for pembrolizumab versus placebo (98.4% CI, 0.43-0.74; P <.0001). There were no new safety concerns in the KEYNOTE-054 trial compared with outcomes reported in previous studies of the PD-1 inhibitor.

Related Videos
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB